NCT03517319View on ClinicalTrials.gov

Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity

PHASE4UnknownINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

June 30, 2018

Conditions
Spasticity as Sequela of Stroke
Interventions
DRUG

Normal Saline 0.9% 1.2 ml

DRUG

Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U

DRUG

Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U

DRUG

Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U

DRUG

Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U

Trial Locations (1)

156-707

RECRUITING

Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

lead

Seoul National University Hospital

OTHER